Get the Stockscreener App
10.78
5.02%
-0.57
After Hours:
10.74
-0.04
-0.37%
Anavex Life Sciences Corporation stock is traded at $10.78, with a volume of 1.62M.
It is down -5.02% in the last 24 hours and down -2.97% over the past month.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.
See More
Previous Close:
$11.35
Open:
$11.32
24h Volume:
1.62M
Relative Volume:
1.62
Market Cap:
$920.79M
Revenue:
-
Net Income/Loss:
$-43.16M
P/E Ratio:
-19.60
EPS:
-0.55
Net Cash Flow:
$-29.31M
1W Performance:
-1.01%
1M Performance:
-2.97%
6M Performance:
+23.91%
1Y Performance:
+75.00%
1-Day Range:
$10.50
$11.70
1-Week Range:
$10.50
$11.70
52-Week Range:
$4.9301
$14.44
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
Name
Anavex Life Sciences Corporation
Sector
Industry
Phone
844-689-3939
Address
630 5TH AVENUE, NEW YORK
Compare AVXL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corporation
|
10.78 | 946.42M | 0 | -43.16M | -29.31M | -0.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Sep-23-21 | Initiated | BTIG Research | Buy |
| Dec-16-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-28-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-27-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-18-19 | Initiated | Janney | Buy |
| May-16-18 | Resumed | Maxim Group | Buy |
| Mar-08-18 | Initiated | ROTH Capital | Buy |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Feb-07-17 | Initiated | Noble Financial | Buy |
| Mar-29-16 | Initiated | FBR Capital | Outperform |
View All
Anavex Life Sciences Corporation Stock (AVXL) Latest News
Anavex Life Sciences: Fiscal Q3 Earnings Snapshot - San Francisco Chronicle
Earnings call transcript: Anavex Life Sciences Q3 2025 sees R&D drop - Investing.com UK
Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update - The Globe and Mail
Anavex Life Sciences Corp. Q3 Loss Increases, Misses Estimates - Nasdaq
Anavex Life Sciences Fiscal Q3 Loss Widens - MarketScreener
Anavex Life Sciences Corp. Reports Q3 Fiscal 2025 Financial Results and Webcast Announcement - Quiver Quantitative
Anavex Reports Breakthrough: Oral Alzheimer's Drug Maintains Benefits After 4 Years as Cash Position Tops $100M - Stock Titan
Anavex Life Sciences Amends Executive Employment Contracts - MSN
How high can Anavex Life Sciences Corp. stock goRSI and MACD Signal Summary with Trends - Newser
Understanding Anavex Life Sciences Corp.’s price movementSmart Trade Mapping with Entry Details - Newser
Why Anavex Life Sciences Corp. stock attracts strong analyst attentionSwing Watchlist With Tight Stop Placement - Newser
Sector ETF performance correlation with Anavex Life Sciences Corp.Stock Entry Points Based on Technicals - Newser
Historical volatility pattern of Anavex Life Sciences Corp. visualizedEquity Portfolio Outlook and Performance Summary - Newser
Real time social sentiment graph for Anavex Life Sciences Corp.Market Sentiment Tracker with Smart Alerts - Newser
What technical models suggest about Anavex Life Sciences Corp.’s comebackPrice Movement and Market Sentiment Analysis - Newser
Published on: 2025-08-10 02:07:10 - Newser
Can a trend reversal in Anavex Life Sciences Corp. lead to recoveryYearly Trend Summary and Opportunity Breakdown - Newser
Can Anavex Life Sciences Corp. recover in the next quarterROI Focused Setup Screener With Exit Markers - Newser
How Resilient Is Anavex Life Sciences Corp. Stock During Economic DownturnsFree Risk Controlled Short Term Trade Plans - Newser
Is Anavex Life Sciences Corp. stock reversal real or fakeIntraday Price Forecast Using Volume Models - Newser
Will Anavex Life Sciences Corp. outperform the marketVolume Spike Detection for Early Breakouts - Newser
Risk adjusted return profile for Anavex Life Sciences Corp. analyzedChart Signal and Short-Term Forecast Tracker - Newser
Envestnet Asset Management Inc. Sells 6,064 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
D. Boral Capital Reiterates Buy Rating for Anavex Life Sciences (NASDAQ:AVXL) - Defense World
Identifying reversal signals in Anavex Life Sciences Corp.Trend Following Ideas with Volume Confirmation - Newser
Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Finan - GuruFocus
Anavex Life Sciences Corp. Schedules Third Quarter Financial Results and Conference Call for August 12, 2025 - Quiver Quantitative
Anavex Life Sciences Earnings: Latest Updates on Alzheimer's and Parkinson's Drug Development Coming August 12 - Stock Titan
Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025 - The Manila Times
Alzheimer's Disease Disease-Modifying Therapies Markets, 2023-2025 & 2026-2030 | Key Marketed Products, Clinical Trials, Competitive Scenario and R&D Activities - GlobeNewswire Inc.
What data driven models say about Anavex Life Sciences Corp.’s futureFree Stock Market Watch With Alerts - Newser
Can Anavex Life Sciences Corp. rally from current levelsHigh Confidence Strategy with Trend Alignment - Newser
Is Anavex Life Sciences Corp. stock a growth or value playDay Trading Setup Forecast with Trend Model - Newser
What catalysts could drive Anavex Life Sciences Corp. stock higher in 2025Maximize your gains with expert trading tips - Jammu Links News
What institutional investors are buying Anavex Life Sciences Corp. stockGet real-time alerts on top-performing stocks - Jammu Links News
Should I hold or sell Anavex Life Sciences Corp. stock in 2025Get timely alerts on market movers - Jammu Links News
Is it the right time to buy Anavex Life Sciences Corp. stockMassive stock growth - Jammu Links News
What are analysts’ price targets for Anavex Life Sciences Corp. in the next 12 monthsOutstanding investment returns - Jammu Links News
Anavex Life Sciences Corporation Stock (AVXL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anavex Life Sciences Corporation Stock (AVXL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MISSLING CHRISTOPHER U | President and CEO |
Mar 24 '25 |
Option Exercise |
0.92 |
500,000 |
460,000 |
1,750,210 |
0.91%
3.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):